SCHEMBL1742219

SCHEMBL1742219

CC1CC(=O)CC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884597 0.74
SCHEMBL21147818 0.74 CA1 (0.41)
SCHEMBL19545969 0.74 CA1 (0.41)
SCHEMBL13865279 0.74 CA1 (0.41)
SCHEMBL26383024 0.74 CA1 (0.41)
SCHEMBL21147819 0.74 CA1 (0.41)
SCHEMBL844526 0.73
SCHEMBL12808170 0.73
SCHEMBL20713955 0.72
SCHEMBL359577 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 US disclosed
US-11739269-B2 Additive and application thereof DAXIN MATERIALS CORPORATION (TW) 2023-08-29 US disclosed
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-05-25 US disclosed
WO-2023083343-A1 POLYCYCLIC COMPOUNDS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2023-05-19 WO disclosed
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-05-09 US disclosed
US-20210299285-A1 COMPOUNDS USEFUL FOR IN VIVO IMAGING OF PROTEIN OXIDATION AND/OR CANCER TREATMENT UNIV WAKE FOREST HEALTH SCIENCES (US) 2021-09-30 US disclosed
US-10040838-B2 CRHR2 peptide agonists and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2018-08-07 US disclosed
US-20170326250-A1 CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF NOVARTIS AG (CH) 2017-11-16 US disclosed
US-20170290878-A1 METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES ENDOCYTE INC (US) 2017-10-12 US disclosed
US-20080015151-A1 CYANOVIRIN VARIANT-POLYMER CONJUGATES THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF (US) 2008-01-17 US disclosed
US-20070287817-A1 Mixture Composition Containing Unsaturated Carboxylic Acid and Alkene Ether Derivative Based Copolymers and Copolymers and Terpolymers Containing Sulfo Groups and Use Thereof CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) 2007-12-13 US disclosed
US-7232805-B2 Cobalamin conjugates for anti-tumor therapy INFLABLOC PHARMACEUTICALS, INC. (US) 2007-06-19 US disclosed
EP-0906432-B1 RECOMBINANT ALPHA-2,3-SIALYLTRANSFERASES AND THEIR USES CA NAT RESEARCH COUNCIL (CA) 2004-06-09 EP disclosed
US-6210933-B1 AMINO ACID SEQUENCE; FOR ADDING SIALIC ACIDS TO GLYCOPROTEINS, GLYCOLIPIDS, AND OTHER ACCEPTOR MOLECULES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2001-04-03 US disclosed
US-6096529-A FROM NEISSERIA SPECIES; FOR SYNTHESIS OF DESIRED OLIGOSACCHARIDES WITH BIOLOGICAL ACTIVITY NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2000-08-01 US disclosed
EP-0906432-A1 RECOMBINANT ALPHA-2,3-SIALYLTRANSFERASES AND THEIR USES National Research Council of Canada (CA) 1999-04-07 EP disclosed
WO-1997047749-A1 RECOMBINANT α-2,3-SIALYLTRANSFERASES AND THEIR USES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1997-12-18 WO disclosed
US-4546104-A Pyrazolopyridine cycloalkanones and process for their preparation ICI AMERICAS INC. (US) 1985-10-08 US disclosed
EP-0141608-A2 Pyrazolopyridine cycloalkanone derivatives ICI AMERICAS INC. (US) 1985-05-15 EP disclosed